See more : B&P Co.,Ltd. (7804.T) Income Statement Analysis – Financial Results
Complete financial analysis of Retractable Technologies, Inc. (RVP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Retractable Technologies, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Askari Metals Limited (AS2.AX) Income Statement Analysis – Financial Results
- Coelacanth Energy Inc. (CEIEF) Income Statement Analysis – Financial Results
- Inventergy Global, Inc. (INVT) Income Statement Analysis – Financial Results
- Zoetis Inc. (0M3Q.L) Income Statement Analysis – Financial Results
- Community West Bancshares (CWBC) Income Statement Analysis – Financial Results
Retractable Technologies, Inc. (RVP)
About Retractable Technologies, Inc.
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43.60M | 94.82M | 188.38M | 81.86M | 41.80M | 33.27M | 34.49M | 29.83M | 29.55M | 34.52M | 30.79M | 33.64M | 32.10M | 36.22M | 38.98M | 27.90M | 26.29M | 25.32M | 24.24M | 21.52M | 19.08M | 20.32M | 16.15M | 9.64M |
| Cost of Revenue | 34.49M | 66.57M | 93.03M | 44.85M | 27.66M | 23.05M | 24.52M | 19.48M | 18.99M | 22.50M | 20.48M | 22.47M | 21.20M | 23.82M | 25.47M | 19.67M | 18.30M | 17.78M | 15.43M | 16.41M | 14.65M | 14.99M | 13.32M | 7.88M |
| Gross Profit | 9.11M | 28.25M | 95.35M | 37.01M | 14.14M | 10.22M | 9.97M | 10.34M | 10.57M | 12.02M | 10.31M | 11.18M | 10.90M | 12.40M | 13.52M | 8.23M | 7.99M | 7.55M | 8.81M | 5.11M | 4.42M | 5.33M | 2.82M | 1.76M |
| Gross Profit Ratio | 20.89% | 29.80% | 50.62% | 45.21% | 33.83% | 30.72% | 28.91% | 34.67% | 35.75% | 34.82% | 33.49% | 33.22% | 33.96% | 34.25% | 34.67% | 29.49% | 30.39% | 29.80% | 36.34% | 23.75% | 23.19% | 26.21% | 17.48% | 18.30% |
| Research & Development | 581.17K | 525.73K | 901.38K | 574.53K | 516.10K | 621.37K | 740.57K | 571.84K | 607.53K | 616.78K | 837.07K | 871.85K | 815.02K | 885.45K | 1.03M | 1.07M | 1.07M | 958.80K | 934.21K | 626.94K | 561.14K | 337.93K | 756.54K | 899.15K |
| General & Administrative | 14.31M | 24.04M | 17.38M | 8.30M | 6.43M | 6.78M | 8.35M | 8.80M | 9.33M | 9.60M | 10.99M | 10.02M | 10.74M | 14.26M | 18.81M | 12.77M | 16.86M | 13.30M | 10.75M | 12.48M | 9.77M | 8.58M | 0.00 | 0.00 |
| Selling & Marketing | 5.71M | 4.54M | 4.48M | 4.06M | 4.22M | 4.40M | 4.66M | 4.03M | 3.84M | 3.97M | 4.41M | 4.22M | 3.44M | 3.67M | 4.37M | 4.84M | 5,299.16B | 5.55B | 4.15B | 3.65M | 3.37M | 4.04M | 0.00 | 0.00 |
| SG&A | 20.01M | 28.58M | 21.86M | 12.36M | 10.65M | 11.18M | 13.01M | 12.82M | 13.17M | 13.56M | 15.40M | 14.24M | 14.18M | 17.93M | 23.19M | 17.61M | 16.86M | 13.30M | 10.75M | 12.48M | 9.77M | 8.58M | 8.78M | 10.37M |
| Other Expenses | 0.00 | -3.83M | -425.16K | 0.00 | 0.00 | 0.00 | 0.00 | 456.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 365.30M | 2,594.60B | 18.67B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.32M | 8.78M | 10.37M |
| Operating Expenses | 20.60M | 25.27M | 22.33M | 12.94M | 11.17M | 11.80M | 13.75M | 13.39M | 13.77M | 14.18M | 16.24M | 15.12M | 14.99M | 18.82M | 24.22M | 18.67M | 17.94M | 14.26M | 11.68M | 13.11M | 10.33M | 11.23M | 9.54M | 11.27M |
| Cost & Expenses | 55.09M | 91.84M | 115.36M | 57.79M | 38.83M | 34.86M | 38.27M | 32.88M | 32.76M | 36.68M | 36.72M | 37.58M | 36.19M | 42.63M | 49.68M | 38.34M | 36.24M | 32.04M | 27.11M | 29.52M | 24.98M | 26.22M | 22.86M | 19.15M |
| Interest Income | 1.45M | 9.95K | 780.00K | 2.26M | 351.17K | 144.12K | 65.70K | 26.52K | 24.92K | 33.94K | 38.94K | 47.00K | 62.60K | 32.32K | 57.60K | 855.69K | 1.87M | 1.98M | 1.37M | 475.12K | 44.55K | 10.04K | 51.94K | 204.20K |
| Interest Expense | 152.17K | 170.65K | 227.18K | 260.26K | 166.90K | 177.19K | 210.76K | 213.30K | 219.67K | 222.81K | 230.58K | 231.21K | 240.48K | 302.84K | 21.89K | 54.36K | 326.30K | 411.15K | 339.69K | 243.92K | 307.14K | 446.39K | 553.62K | 203.78K |
| Depreciation & Amortization | 7.53M | 4.60M | 1.26M | 832.07K | 852.08K | 886.81K | 834.95K | 872.87K | 858.39K | 1.07M | 1.28M | 1.34M | 1.31M | 1.52M | 1.40M | 1.40M | 1.43M | 1.43M | 1.37M | 1.29M | 1.31M | 1.33M | 1.20M | 938.57K |
| EBITDA | -1.24M | 9.94M | 76.44M | 27.17M | 4.18M | -289.26K | -2.88M | -2.61M | 5.40M | -1.05M | -4.61M | -2.56M | 2.98M | 4.04M | -11.84M | -8.19M | -6.66M | -3.31M | -137.09K | -8.00M | -4.59M | -4.58M | -5.52M | -8.57M |
| EBITDA Ratio | -2.84% | 8.01% | 39.84% | 33.18% | 9.99% | -1.65% | -8.34% | -7.21% | -7.87% | -3.04% | -14.97% | -7.60% | -8.46% | -13.44% | -23.72% | -29.36% | -32.39% | -20.88% | -6.23% | -377.94% | -96.83% | -8.75% | -34.17% | -88.87% |
| Operating Income | -11.49M | 2.99M | 72.60M | 24.07M | 2.97M | -1.32M | -3.78M | -3.51M | -3.21M | -2.16M | -5.93M | -3.94M | -4.09M | -6.78M | -13.30M | -10.44M | -9.95M | -6.71M | -2.88M | -8.00M | -5.90M | -6.39M | -6.71M | -10.45M |
| Operating Income Ratio | -26.35% | 3.15% | 38.54% | 29.40% | 7.11% | -3.97% | -10.95% | -11.76% | -10.85% | -6.25% | -19.27% | -11.71% | -12.74% | -18.72% | -34.11% | -37.44% | -37.83% | -26.51% | -11.87% | -37.17% | -30.94% | -31.45% | -41.58% | -108.33% |
| Total Other Income/Expenses | 2.57M | 6.02M | 2.36M | 2.00M | 184.27K | 236.78K | -145.07K | -642.89K | 7.53M | -188.87K | -191.64K | -184.21K | 5.52M | 8.64M | -2.56M | 801.33K | 1.54M | 1.57M | 1.03M | 74.87M | 13.62M | -436.36K | 0.00 | 734.79K |
| Income Before Tax | -8.92M | 5.16M | 74.95M | 26.07M | 3.16M | -1.35M | -3.92M | -3.69M | 4.32M | -2.35M | -6.12M | -4.12M | 1.43M | 2.22M | -13.26M | -9.64M | -8.40M | -5.15M | -1.84M | 66.87M | 7.71M | -6.83M | 0.00 | 0.00 |
| Income Before Tax Ratio | -20.45% | 5.44% | 39.79% | 31.85% | 7.55% | -4.07% | -11.37% | -12.38% | 14.63% | -6.80% | -19.89% | -12.25% | 4.46% | 6.14% | -34.02% | -34.57% | -31.96% | -20.33% | -7.61% | 310.70% | 40.43% | -33.60% | 0.00% | 0.00% |
| Income Tax Expense | -1.91M | 83.87K | 18.89M | 1.85M | 7.88K | -13.32K | -187.61K | 1.13K | 7.88K | 8.18K | 90.97K | 9.82K | 13.80K | -176.06K | -3.84M | 855.69K | -1.45M | -1.28M | -605.36K | 12.18M | 265.47K | 917.99K | 501.67K | 938.15K |
| Net Income | -7.01M | 5.08M | 56.06M | 24.22M | 3.15M | -1.34M | -3.74M | -3.69M | 4.31M | -2.35M | -6.21M | -4.13M | 1.42M | 2.40M | -9.42M | -9.64M | -6.95M | -3.87M | -1.24M | 54.69M | 7.45M | -6.83M | -7.22M | -10.44M |
| Net Income Ratio | -16.08% | 5.36% | 29.76% | 29.59% | 7.53% | -4.03% | -10.83% | -12.39% | 14.60% | -6.82% | -20.18% | -12.28% | 4.42% | 6.63% | -24.17% | -34.57% | -26.43% | -15.28% | -5.11% | 254.12% | 39.04% | -33.60% | -44.69% | -108.33% |
| EPS | -0.24 | 0.15 | 1.65 | 0.80 | 0.07 | -0.04 | -0.12 | -0.13 | 0.21 | -0.09 | -0.23 | -0.16 | 0.02 | 0.04 | -0.40 | -0.41 | -0.29 | -0.16 | -0.05 | 2.33 | 0.23 | -0.34 | -0.36 | -0.71 |
| EPS Diluted | -0.24 | 0.15 | 1.63 | 0.80 | 0.07 | -0.04 | -0.12 | -0.13 | 0.20 | -0.09 | -0.23 | -0.16 | 0.02 | 0.04 | -0.40 | -0.41 | -0.29 | -0.16 | -0.05 | 2.33 | 0.20 | -0.34 | -0.36 | -0.54 |
| Weighted Avg Shares Out | 29.94M | 32.90M | 33.87M | 33.17M | 32.67M | 32.67M | 31.72M | 29.33M | 27.82M | 27.25M | 27.00M | 26.22M | 24.17M | 23.87M | 23.81M | 23.79M | 23.73M | 23.59M | 23.33M | 22.60M | 21.00M | 20.30M | 19.77M | 14.72M |
| Weighted Avg Shares Out (Dil) | 29.94M | 32.96M | 34.24M | 33.30M | 32.67M | 32.67M | 31.96M | 29.35M | 29.48M | 27.38M | 27.00M | 26.22M | 26.35M | 26.25M | 23.81M | 23.79M | 23.73M | 23.59M | 23.33M | 25.48M | 24.44M | 20.30M | 19.77M | 19.37M |
Retractable Technologies, Inc. Results for the Periods Ended September 30, 2024
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $10.3 million for the third quarter of 2024 and an operating loss of $5.1 million for the period, as compared to total net sales for the...
Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of...
Retractable Technologies, Inc. Files Complaint in United States Court of International Trade
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) announces that on September 26, 2024, it filed a complaint in the United States Court of International Trade against defendants involved in the issuance of a recent decision implementing a 100%...
Tariffs Finalized on Chinese Imports
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) announces that on September 13, 2024, the Office of the United States Trade Representative (“USTR”) revealed final adjustments to tariffs placed on Chinese imported syringes and needles. Despite initially proposing a...
Retractable Technologies, Inc. Results for the Period Ended March 31, 2024
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $7.6 million for the first three months of 2024 and an operating loss of nearly $3.0 million for the period, as compared to total net sales...
Retractable Technologies, Inc. Reports Results for 2023
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2023. Further details concerning the results of operations as well as other matters are available in Retractable's Form 10-K filed...
Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of...
3 Stocks with Major Insider Buying This Month
Active traders use many fundamental or technical signals to set up their trades. Stocks exhibiting heavy insider buying can be one of these signals.
Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of...
Retractable Technologies, Inc. Not Impacted by FDA Safety Communication
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports that the FDA Safety Communication “Evaluating Plastic Syringes Made in China for Potential Device Failures” on November 30, 2023 does not refer to syringes from Retractable Technologies Inc. The FDA...
Source: https://incomestatements.info
Category: Stock Reports